Please login to the form below
Infographic: Pharma investment in Indonesia
Pharma deals in the region since the introduction of Decree 1010 to force companies to manufacture products locally
In 2008, the government in Indonesia released Decree 1010, meaning all foreign pharma companies working in the country had to manufacture drugs locally or form a partnership with a local manufacturer in order to register their own medicines.
This infographic details all the agreements formed by pharma companies in the region in the five years since Decree 1010 was published.
The affected pharma companies are MSD, Sanofi, Servier, AstraZeneca, Novo Nordisk, Lilly, Janssen- Cilag, Astellas, Wyeth, Roche and PT Orshonovo.
Read the accompanying article on pharma investment in Indonesia
2013: Five years after Decree 1010 - what has changed in Indonesia?
(Click on the image for a larger version)
COVID-19 Updates and Daily News
Featured jobs
-
Head of Copy
-
£ competitive
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Graduate Business Analyst, Healthcare Communications – Pharma/ S...
-
Highly competitive salary
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Editorial Team Leader, Medical Communications, Oxford
-
Competitive Salary
- AstraZeneca’s Imfinzi and tremelimumab show unprecedented survival rate in liver cancer patients
- Sanofi and Regeneron’s Dupixent receives second positive phase 3 trial results
- Why pharma must get smart in its approach to customer engagement
- AstraZeneca's Enhertu receives FDA grant for priority review
- Merck and Eisai share crucial phase 3 trial results for advanced endometrial carcinoma treatment
- Pfizer’s Cibinqo granted FDA approval for adults with moderate-to-severe atopic dermatitis
- PM announces plans to lift England’s COVID-19 restrictions
- Merck and Eisai share crucial phase 3 trial results for advanced endometrial carcinoma treatment
- Developing Innovative Digital Strategies to Engage Patients
- GSK appoint Tony Wood as chief scientific officer
- Sanofi and Regeneron’s Dupixent receives second positive phase 3 trial results
- Cervical Cancer Prevention Month
- Why pharma must get smart in its approach to customer engagement
- Pfizer lifts 2021 guidance as sales of its BioNTech-partnered vaccine continue to climb
- AstraZeneca's Enhertu receives FDA grant for priority review
- AZ’s PNH therapy Ultomiris wins EU backing to expand use for children
- J&J’s COVID-19 booster shows 85% effectiveness in preventing hospitalisation for COVID-19 in study
- Sanofi and Exscientia agree on a deal worth up to $5.2bn for AI-driven therapies
